Business

Know the Business — Zoetis Inc.

Zoetis is the global #1 in animal health: a branded, self-pay specialty manufacturer whose economics look more like consumer pet-care brands than human pharma. The model compounds because chronic-dose drugs (parasiticides, dermatology, OA-pain monoclonals) renew monthly and ride in through ~3,900 sales reps directly to the veterinarian — who is also the dispensing point. The thing the market keeps re-learning the hard way is concentration: the top five product lines do 42% of revenue, so a single LOE (Convenia/Cerenia in Q1 2026) can reset the multiple even when the rest of the business is fine.

1. How This Business Actually Works

Zoetis takes a patented molecule or vaccine antigen, runs a species-specific trial (cheaper and faster than human trials), gets one regulator's nod per country, and ships it through a salesforce that the vet trusts — not a PBM, not a payer. Pet owners and farmers pay in cash. No formulary, no rebates, no monopsony — a brand sold to a fragmented end market through a captive professional channel.

The non-obvious mechanic is the vet as gatekeeper. In US human retail pharmacy, a $4 generic at CVS substitutes for a $200 brand the moment the script is dropped. In the vet clinic, the same physician is making the recommendation, stocking the inventory, and ringing the sale — so brand loyalty earns the manufacturer a 30-60% revenue tail for years after exclusivity ends, instead of an overnight cliff. That tail is also why ZTS will not earn the cliff-free compounder multiple some bulls want: the tail still erodes, and the market repeatedly underestimates the speed of erosion on individual molecules (Draxxin -66% in five years, Rimadyl chewable -39%).

Companion-animal is the right side of the industry: higher gross margin, faster growth, recession-resilient (pet owners cut entertainment and clothing before vet bills). Livestock is the lower-margin half, exposed to protein cycles, feed costs, and disease outbreaks. The companion tilt is what earns the 37%+ operating margin; long-run mix has been drifting that way.

2. The Playing Field

The peer set tells a clean story. ZTS is the only pure-play with scale, leadership, and full-stack therapeutic + diagnostics + biologics. Below it sit a leveraged turnaround (ELAN), a diagnostics razor-and-blade leader (IDXX) that competes adjacent but with better ROIC, and a long tail of smaller pure-plays. The Big Pharma animal-health segments (Merck AH, Boehringer AH) compete in the trenches but are invisible at the consolidated multiple level — Keytruda and immuno-oncology drown the segment out.

MRK and PFE are full-company; animal health is one segment of a much larger pharma business and the multiples are not directly comparable.

Three things the table makes obvious. One, ZTS is the only therapeutic pure-play that combines scale, margin, and double-digit ROIC at the same time — ELAN proves that the industry's structural tailwinds do not automatically produce returns if leverage and integration go wrong. Two, IDXX earns a higher ROIC than ZTS on lower gross margin because diagnostics is razor-and-blade (low-cost analyzer placed in a clinic, then a multi-year consumables annuity) — that is a different model with different reinvestment math, and explains why IDXX trades at 36x EV/EBITDA versus ZTS at 15x. Three, the EU pure-play (Virbac) shows what mid-tier scale looks like: 15% operating margins, 12% ROIC, single-digit FCF margin. Scale is real in this industry.

3. Is This Business Cyclical?

Not cyclical in the macro sense, but materially exposed to two specific shocks that look nothing like a normal recession: livestock-disease outbreaks and patent-cliff erosion on individual molecules. Companion-animal demand barely moves with GDP because spend is small per household and emotionally non-discretionary; livestock can swing 10-20% on disease or feed-price spikes; LOE events are the most reliable mispricing because the curve is steep and visible in advance.

Through one global recession, one pandemic, one major LOE (Draxxin), one livestock disease (ASF), and inflation 2022-23, operating margin ratcheted up almost monotonically from 15.7% to 37.5%. The only "cycles" that meaningfully hit the P&L are molecule-specific LOEs (which decay over 3-5 years, not a quarter) and regional livestock disease outbreaks (which whipsaw a segment, not the company). The 2026 reset is a third type: a single-quarter optics shock that interrupts the compound — whether it breaks the engine is what the next two prints test.

4. The Metrics That Actually Matter

Most ratios for ZTS read like a textbook quality compounder — they tell you what already happened. The five metrics below are the ones that change before the stock does.

The ROIC line is the punchline of the franchise: scale plus mix plus brand has compounded the return on invested capital from 9% to 26% over a decade while the company nearly tripled revenue. That is the structural reason this stock has historically traded at a premium multiple — but a meaningful and durable ROIC compression (say, sustained drift below 20%) would be a real signal, not noise.

5. What Is This Business Worth?

The right lens is cash earnings power — normalized free cash flow through the next LOE cycle, at the multiple a #1 self-pay specialty brand owner should command. Not SOTP: the two segments (US, International) share the same products, same R&D, same factories, same mAb pipeline. Not P/B: tangible book is negative (-$434M) because $7B+ of buybacks have wiped out book equity. Not deeply-discounted-cycle: this isn't a commodity cycle, it's a slow LOE replacement.

6. What I'd Tell a Young Analyst

Watch the molecules, not the company. The macro doesn't move this stock — patent cliffs and product launches do. Build a table of every product over $200M in revenue, its patent and regulatory exclusivity, and its post-LOE erosion curve assumption; that table is your model. Treat the Big Four oligopoly as a real structural moat (no Teva exists in this industry, and won't) and treat brand loyalty post-LOE as real but bounded — 30-60% revenue loss over 3-5 years is the empirical curve, not the bull-case 10%.

The single most useful question to ask each quarter is: what is the operational, constant-FX, organic growth of companion-animal in the US? Above 6% the franchise is healthy. Between 0% and 6% it is harvesting. Negative for two quarters in a row means a real cliff is happening, not a hiccup. The May 2026 reset was an extreme version of that signal arriving live.

Three things the market habitually misprices on this name: (1) it confuses a strong quarter for the end of LOE drag — the curve runs for years; (2) it pays for IDEXX-like multiples on the companion-animal therapeutic engine without crediting the IDEXX-like ROIC profile that justifies them, then complains when ZTS trades at 15x EV/EBITDA instead of 35x; (3) it treats Librela's category-creating economics as recurring and the eventual mAb competitive entries as theoretical.

Finally, watch capital allocation. ZTS retired 2.3% of its shares in FY25 alone and raised the dividend; if buyback pace accelerates while M&A discipline holds (no megadeals), that is the single best signal management believes the LOE replacement engine is intact. A transformative acquisition at a premium price is the value-destruction scenario specialty pharma has run through twice in a decade.